Bestoun Ahmed1, Wendy C King2, William Gourash3, Steven H Belle4, Amanda Hinerman2, Alfons Pomp5, Greg Dakin5, Anita P Courcoulas3. 1. Department of Surgery, Division of Minimally Invasive Bariatric and General Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: ahmedbh2@upmc.edu. 2. Graduate School of Public Health, Epidemiology, University of Pittsburgh, Pittsburgh, PA. 3. Department of Surgery, Division of Minimally Invasive Bariatric and General Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. 4. Graduate School of Public Health, Epidemiology & Biostatistics, University of Pittsburgh, Pittsburgh, PA. 5. Department of Surgery, Division of GI, Metabolic & Bariatric Surgery, Weill Cornell Medicine, New York, NY.
Abstract
BACKGROUND: Data from a US multicenter longitudinal study of bariatric surgery were used to compare weight change (primary outcome) and comorbidities (secondary outcome) in patients who underwent sleeve gastrectomy versus Roux-en-Y gastric bypass. METHODS: This study includes participants who underwent sleeve gastrectomy and matched participants who underwent Roux-en-Y gastric bypass from the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) study. Adults undergoing initial bariatric surgical procedures between 2006 and 2009 were enrolled. Participants who underwent sleeve gastrectomy were high-risk or superobese and intended to have a second-stage procedure. Mixed models were used to evaluate percent weight change from baseline through 7 years, and diabetes, dyslipidemia, and hypertension prevalence through 5 years. RESULTS: Fifty-seven of 59 participants who underwent sleeve gastrectomy were matched one to one. Most were female (68%) and white (81%), and had a median age of 49 (37-56) years and median body mass index of 56.4 (35.5-76.8) kg/m2 presurgery. Weight loss was significantly less 1 to 7 years after sleeve gastrectomy versus matched Roux-en-Y gastric bypass (eg, year 7 mean weight loss was 23.6% vs 30.4%, respectively; P = .001). For both surgical groups, prevalence of diabetes, low high-density lipoprotein, and hypertension were significantly (P < .05) lower 5 years postsurgery versus baseline. CONCLUSION: Higher-risk or super-obese participants after sleeve gastrectomy lost less weight than did matched Roux-en-Y gastric bypass counterparts throughout 7 years. Both groups exhibited improvements in comorbidities from presurgery through 5 years.
BACKGROUND: Data from a US multicenter longitudinal study of bariatric surgery were used to compare weight change (primary outcome) and comorbidities (secondary outcome) in patients who underwent sleeve gastrectomy versus Roux-en-Y gastric bypass. METHODS: This study includes participants who underwent sleeve gastrectomy and matched participants who underwent Roux-en-Y gastric bypass from the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) study. Adults undergoing initial bariatric surgical procedures between 2006 and 2009 were enrolled. Participants who underwent sleeve gastrectomy were high-risk or superobese and intended to have a second-stage procedure. Mixed models were used to evaluate percent weight change from baseline through 7 years, and diabetes, dyslipidemia, and hypertension prevalence through 5 years. RESULTS: Fifty-seven of 59 participants who underwent sleeve gastrectomy were matched one to one. Most were female (68%) and white (81%), and had a median age of 49 (37-56) years and median body mass index of 56.4 (35.5-76.8) kg/m2 presurgery. Weight loss was significantly less 1 to 7 years after sleeve gastrectomy versus matched Roux-en-Y gastric bypass (eg, year 7 mean weight loss was 23.6% vs 30.4%, respectively; P = .001). For both surgical groups, prevalence of diabetes, low high-density lipoprotein, and hypertension were significantly (P < .05) lower 5 years postsurgery versus baseline. CONCLUSION: Higher-risk or super-obeseparticipants after sleeve gastrectomy lost less weight than did matched Roux-en-Y gastric bypass counterparts throughout 7 years. Both groups exhibited improvements in comorbidities from presurgery through 5 years.
Authors: Guilherme S Mazzini; Jad Khoraki; Matthew G Browning; Bernardo M Pessoa; Luke G Wolfe; Guilherme M Campos Journal: Obes Surg Date: 2020-03 Impact factor: 4.129
Authors: Matthew Stevenson; Ankita Srivastava; Jenny Lee; Christopher Hall; Thomas Palaia; Raymond Lau; Collin Brathwaite; Louis Ragolia Journal: Obes Surg Date: 2021-04-15 Impact factor: 4.129
Authors: Hassan Nasser; Tommy Ivanics; Oliver A Varban; Jonathan F Finks; Aaron Bonham; Amir A Ghaferi; Arthur M Carlin Journal: Surg Endosc Date: 2020-06-22 Impact factor: 4.584
Authors: Michael J Devlin; Wendy C King; Melissa A Kalarchian; Amanda Hinerman; Marsha D Marcus; Susan Z Yanovski; James E Mitchell Journal: Int J Eat Disord Date: 2018-12-06 Impact factor: 4.861
Authors: Susan K Raatz; LuAnn K Johnson; Alicia Caliquary; Wendy C King; Melissa A Kalarchian; Michael J Devlin; Marsha D Marcus; James E Mitchell Journal: Surg Obes Relat Dis Date: 2020-04-22 Impact factor: 4.734
Authors: R de La Harpe; S Rüeger; Z Kutalik; P Ballabeni; M Suter; N Vionnet; B Laferrère; F Pralong Journal: Obes Surg Date: 2020-04 Impact factor: 4.129